Publicaciones en colaboración con investigadores/as de Hospital Universitario Reina Sofia (205)

2024

  1. Association of obesity on the outcome of critically ill patients affected by COVID-19

    Medicina Intensiva, Vol. 48, Núm. 3, pp. 142-154

  2. Clustering COVID-19 ARDS patients through the first days of ICU admission. An analysis of the CIBERESUCICOVID Cohort

    Critical Care, Vol. 28, Núm. 1

  3. Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial

    The Lancet Infectious Diseases, Vol. 24, Núm. 4, pp. 375-385

  4. Patients who suffer a first atherosclerotic cardiovascular event while taking statins are often far off of lipid targets

    Nutrition, Metabolism and Cardiovascular Diseases, Vol. 34, Núm. 1, pp. 90-97

2023

  1. A differential therapeutic consideration for use of corticosteroids according to established COVID-19 clinical phenotypes in critically ill patients

    Medicina Intensiva, Vol. 47, Núm. 1, pp. 23-33

  2. A prognostic score to identify women at increased risk for abnormal uterine bleeding during anticoagulation for venous thromboembolism

    Thrombosis Update, Vol. 13

  3. Effects of intubation timing in patients with COVID-19 throughout the four waves of the pandemic: a matched analysis

    The European respiratory journal, Vol. 61, Núm. 3

  4. Identifying patients with prostate cancer at increased risk for haematuria during anticoagulation for venous thromboembolism

    Thrombosis Research, Vol. 232, pp. 54-61

  5. Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter real-world study

    Frontiers in Endocrinology, Vol. 14

  6. Key Factors Associated With Pulmonary Sequelae in the Follow-Up of Critically Ill COVID-19 Patients

    Archivos de Bronconeumologia, Vol. 59, Núm. 4, pp. 205-215

  7. Procalcitonin and C-reactive protein to rule out early bacterial coinfection in COVID-19 critically ill patients

    Intensive Care Medicine, Vol. 49, Núm. 8, pp. 934-945

  8. Response to glecaprevir/pibrentasvir in HIV/HCV-coinfected patients in clinical practice

    Journal of Antimicrobial Chemotherapy, Vol. 78, Núm. 10, pp. 2591-2596

  9. Sex-Related Differences in Patient Characteristics, Risk Factors, and Symptomatology in Older Adults with Pulmonary Embolism: Findings from the SERIOUS-PE Study

    Seminars in Thrombosis and Hemostasis, Vol. 49, Núm. 7, pp. 725-735

  10. Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results

    Clinical and experimental dermatology, Vol. 48, Núm. 9, pp. 991-997

  11. Upadacitinib for moderate to severe atopic dermatitis

    Immunotherapy, Vol. 15, Núm. 11, pp. 799-808

  12. Updated Review on Treatment of Atopic Dermatitis

    Journal of Investigational Allergology and Clinical Immunology, Vol. 33, Núm. 3, pp. 158-167

  13. Venetoclax is a potent hepsin inhibitor that reduces the metastatic and prothrombotic phenotypes of hepsin-expressing colorectal cancer cells

    Frontiers in Molecular Biosciences, Vol. 10

2022

  1. A microRNA Signature for the Diagnosis of Statins Intolerance

    International Journal of Molecular Sciences, Vol. 23, Núm. 15

  2. Atopic Dermatitis: Background, Objectives and Future Perspectives (Superresponders)

    Life

  3. Clindamycin but not Intravenous Immunoglobulins reduces mortality in a retrospective cohort of critically ill patients with bacteremic Group A Streptococcal infections

    Revista Espanola de Quimioterapia, Vol. 35, Núm. 5, pp. 475-481